Jeffrey M. Leiden
At a glance: Jeffrey M. Leiden is Director at Odyssey Therapeutics (ODTX). Their latest SEC Form 4, filed May 11, 2026, reported a purchase of $100K. On file: 1 purchase line ($100K) and 17 sale lines ($60.9M).
Disclosed holdings: about $5.0M of ODTX stock: 270,198 shares reported on their latest Form 4 (filed May 11, 2026), valued at the Nov 19, 2026 close of $18.43. This counts only ODTX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Odyssey Therapeutics, Inc. (ODTX); Chair at Vertex Pharmaceuticals Inc / Ma (VRTX)
Purchase track record
Not enough history. Based on 1 purchase with a full 90 days of price history.
Jeffrey M. Leiden's InsiderPrint
18 trades from SEC Form 4 filings, 2025 to 2026, drawn as one fingerprint.
Reading this print: Almost only sells, trading about 18 times a year, typically $2.0M a trade; most sales are on a pre-planned 10b5-1 schedule; trades in the same month most years.
- Bump outward: a purchase (1)
- Dent inward: a sale (17)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Shyam SankarSee Remarks · PLTR · 99% match
- Ahn Luis VonCEO, President · DUOL · 99% match
- Roy D. BaynesDirector · NTRA · 94% match
- Insight Holdings Group, LLC10% Owner · COUR · 92% match
- Elizabeth M. AndersonDirector · INSM · 90% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| May 11SEC | ODTXOdyssey Therapeutics, Inc.First buyAbove market priceLikely offeringBought at the IPO | Buy | 5,000270,198 held (+2%) | $20.00 | $100K | -7.8% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 4,46983,338 held (−5%) | $440.40 | $2.0M | +18.4% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 1,32082,018 held (−2%) | $441.26 | $582K | +18.1% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 2,46979,549 held (−3%) | $443.21 | $1.1M | +17.6% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 4,35275,197 held (−5%) | $444.36 | $1.9M | +17.3% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 7,89967,298 held (−11%) | $445.56 | $3.5M | +17.0% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 1,15266,146 held (−2%) | $447.05 | $515K | +16.6% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 2,32063,826 held (−4%) | $448.78 | $1.0M | +16.2% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 5,88057,946 held (−9%) | $449.84 | $2.6M | +15.9% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 5,80952,137 held (−10%) | $451.20 | $2.6M | +15.5% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 15,68136,456 held (−30%) | $452.20 | $7.1M | +15.3% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 10,36026,096 held (−28%) | $453.34 | $4.7M | +15.0% |
| Dec 5SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 2,07024,026 held (−8%) | $455.22 | $942K | +14.5% |
| Nov 17SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 18,52825,186 held (−42%) | $440.22 | $8.2M | +18.4% |
| Nov 17SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 1,16024,026 held (−5%) | $441.05 | $512K | +18.2% |
| Nov 17SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 32,23445,396 held (−42%) | $440.30 | $14.2M | +18.4% |
| Nov 17SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 21,33024,066 held (−47%) | $441.35 | $9.4M | +18.1% |
| Nov 17SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 4024,026 held (−0%) | $442.00 | $18K | +17.9% |
- Buy
Director Jeffrey M Leiden bought $100K of ODTX at $20.00 — first open-market purchase in our records.
- Sell
Chair Jeffrey M Leiden sold $2.0M of VRTX at $440.40 — pre-scheduled 10b5-1 plan sale.
- Sell
Chair Jeffrey M Leiden sold $582K of VRTX at $441.26 — pre-scheduled 10b5-1 plan sale.
- Sell
Chair Jeffrey M Leiden sold $1.1M of VRTX at $443.21 — pre-scheduled 10b5-1 plan sale.
- Sell
Chair Jeffrey M Leiden sold $1.9M of VRTX at $444.36 — pre-scheduled 10b5-1 plan sale.
- Sell
Chair Jeffrey M Leiden sold $3.5M of VRTX at $445.56 — pre-scheduled 10b5-1 plan sale.
Follow Jeffrey M. Leiden
Get one email when Jeffrey M. Leiden files a new purchase or sale. Free.
At most one email a day about Jeffrey M. Leiden, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.